A randomized cross-over controlled study on prevention of myopia in children with 0.01% atropine eye drops

Clinical study on prevention of myopia in children with 0.01% atropine eye drops

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034760

Enrollment

Unknown

Registered

2020-07-18

Start date

2020-07-20

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

group 1:phased I: 0.01% Atropine

phase II: blank solvent

group 2:phase I: blank solvent

phased II: 0.01% Atropine

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Aged 6-12 years; 2. Equivalent spherical degree number: +0.50~-0.75 D, astigmatism less than -1.0 D ; 3. Far and near corrected visual acuity greater than or equal to 1.0.

Exclusion criteria

Exclusion criteria: 1. Previous use of atropine or pirenzepine and training methods to prevent myopia onset. 2. Can not be reviewed regularly. 3. Allergy to atropine. 4. Past/current strabismus or past amblyopia. 5. Active inflammation of the eye; history of ocular trauma or ocular surgery; systemic or ocular organic lesions.

Design outcomes

Primary

Measure	Time frame
refraction diopter;axial length;	—

Secondary

Measure	Time frame
amplitude of accommodation;pupil diameter;	—

Countries

China

Contacts

Public ContactFu Aicun

The First Affiliated Hospital of Zhengzhou University

fuaicun2019@qq.com+86 15093272336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026